Researchers at USC developed an algorithmic tool to improve screening of patients for Alzheimer's clinical trials, reducing unnecessary PET scans by over half. The tool uses blood plasma biomarkers to identify patients at risk of Alzheimer's disease, enabling faster and more efficient recruitment for trials like AHEAD 3-45.
Researchers from the University of Osaka found that a protein associated with amyloidogenic light chain disease forms amyloid in areas of constrained geometry when subjected to shear stress. This study, published in FEBS Journal, suggests that mechanical pressure and chemical inhibitors may help dissolve amyloids.
Researchers suggest that targeting tiny protein aggregates known as oligomers, which form early in the disease process, may lead to breakthroughs in treating protein-misfolding diseases. Oligomers are increasingly believed to drive cellular damage, and their early formation may be more toxic than large protein deposits.
Researchers identify energetic frustration in p53's sequence as a key factor in its fragility. The study shows that p53's flexibility comes at a high cost, allowing it to perform roles but making it prone to misfolding and aggregation. This knowledge offers a roadmap for cancer treatment by targeting specific regions sensitive to water.
Researchers found SIRT6 is essential for maintaining protein homeostasis, regulating the protein life cycle to prevent protein aggregates that contribute to neurodegenerative diseases. Reduced SIRT6 levels play a critical role in aging and age-related neurodegeneration.
A new Cochrane review of 17 clinical trials found that anti-amyloid Alzheimer's drugs have no significant impact on cognitive decline or dementia severity, but may increase the risk of brain swelling and bleeding. The evidence suggests that these drugs are unlikely to provide clear benefit to patients.
SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateApr 15, 2026
A research team at Kumamoto University identified a plant-derived molecule, PGG, that breaks down transthyretin (TTR) amyloid linked to heart and nerve disorders. The study found PGG effectively disassembled amyloid fibrils without disrupting other types of protein aggregates.
A UT Health San Antonio researcher will study how microglia contribute to the spread of toxic tau protein in Alzheimer's disease. The study aims to clarify whether microglia act as barriers or accelerators in the cascade of the disease, potentially leading to new treatments.
A new study from the Stowers Institute has identified a mechanism that makes fleeting moments unforgettable, revealing a critical step in forming long-lasting memories. The research discovered a specific type of chaperone protein that allows proteins to change shape and form functional amyloids that house long-term memory.
Researchers have developed a new class of engineered nanoparticles that can bind to and degrade specific disease-related proteins. This technology has the potential to treat diseases such as dementia and brain cancer by eliminating harmful proteins.
The study reveals how heat shock chaperone proteins Hsp40 and Hsp70 bind each other and misfolded peptides, enabling the cellular machinery to work. The findings also identify a specific region of Hsp40 that handles protein handoffs, which could lead to therapeutic interventions for diseases.
Researchers at the University of Bath develop a peptide fragment that locks alpha-synuclein into its healthy shape, blocking toxic clumps that cause nerve cell death. The breakthrough demonstrates the potential of rational peptide design to transform large proteins into compact drug-like molecules.
Daniel Hebert's life's work details how carbohydrate-related chaperones direct the protein folding process and guide proteins to their ultimate locations. The study highlights the crucial role of N-glycans in tagging misfolded proteins for destruction or correction.
Researchers develop a simplified model of tau protein that forms disease-like fibrils, shedding light on the fundamental interactions underlying neurodegenerative diseases. The 'mini prion' can recreate the critical hallmarks of tauopathies, such as Alzheimer's disease.
A misfolded protein in spinal fluid facilitates reliable Parkinson's diagnosis even in its early stages. The biomarker has a sensitivity and specificity of over 90%, making it a promising tool for disease management and potential therapy development.
A novel AI tool, RibbonFold, predicts the structures of amyloids, revealing previously overlooked nuances in their formation and evolution. This breakthrough may reshape how researchers approach neurodegenerative disease treatment and offers a scalable method for analyzing harmful protein aggregates.
A new Northwestern University study finds that NU-9 improves neuron health in animal models of Alzheimer's disease by addressing the underlying mechanisms of misfolded proteins. The drug reduces protein buildup and prevents inflammation, showing potential for treating neurodegenerative diseases.
Researchers developed an efficient way to predict structures of human proteins that were previously challenging to observe. The algorithm, AlphaFold-Metainference, outperformed existing methods in accuracy and can be applied to other biomolecules like DNA and RNA.
Researchers have discovered Mitofusin 2's unexpected function in maintaining protein quality within cells, interacting with the proteasome and chaperones to prevent toxic aggregates. This novel connection has far-reaching implications for treating CMT and other neurodegenerative diseases.
A new study identified USP5 as an enzyme crucial for breaking down unneeded or damaged proteins in the heart. Low levels of USP5 lead to protein buildup, triggering dilated cardiomyopathy in animal models. Increasing USP5 levels helps clear protein 'junk', improving heart function and reducing disease progression.
Proteins form complexes to fulfill their functions, with assembly often beginning during synthesis. Misfolded proteins can lead to cellular dysfunction and diseases; understanding co-translational assembly may help develop new therapeutic approaches.
A massive study of human protein variants found that 61% of disease-causing mutations destabilize proteins, leading to cataracts, neurological disorders, and muscle-wasting diseases. The researchers created the Human Domainome 1 catalogue, which includes over half a million mutations across 522 human protein domains.
A novel 'reporter' molecule has been developed to detect ER-related problems during protein synthesis, offering simplicity and robustness against environmental fluctuations. The tool uses a firefly luciferase-based system to identify defects in protein translocation and disulfide bond formation.
Researchers at the Buck Institute found that ketone bodies interact directly with misfolded proteins, altering their solubility and structure to be cleared through autophagy. This discovery suggests a new form of metabolic regulation of protein quality control in the brain, with potential therapeutic applications.
A new class of neurological diseases called TRiCopathies has been identified, linked to mutations in a protein complex that helps fold proteins correctly. The study found that patients with intellectual disabilities and seizures have defects in the TRiC complex, which affects brain development and function.
Researchers at Gladstone Institutes created a new mouse model to study Alzheimer's disease, transplanting human neurons into mouse brains. The study found that immune cells called microglia cause harmful inflammation and clumps of misfolded proteins when interacting with the APOE4 protein.
Scientists have developed a polymer-based therapeutic for Huntington’s disease, which disrupts protein interactions to preserve cell health. The treatment successfully rescued neurons and reversed symptoms in mouse studies, showing promise as a potential delay or reduction of disease onset.
Scientists have successfully imaged superspreader fibrils in the brain tissue of Alzheimer's patients, shedding light on their role in spreading the disease. The study, published in Science Advances, uses advanced imaging techniques to visualize the fibrils' formation and spread.
A new study found that toxic SOD1 protein trimers interact with various proteins in different tissues, contributing to cellular dysfunction and degeneration in ALS. Septin-7 is identified as a potential therapeutic target, potentially slowing or disrupting ALS progression.
Scientists at Sanford Burnham Prebys have developed a clearer picture of how crucial machinery in the human cell's recycling process for obsolete and misshapen proteins—known as proteasomes—are formed. The research team shed new light on how two protein chaperones bind on the top of the alpha subunit ring as it is constructed.
Researchers have identified a protein, RNF114, that reverses cataracts by facilitating protein degradation. This discovery may lead to a surgery-free treatment strategy for managing cataracts, a common cause of vision loss worldwide.
Scientists have developed new therapies that selectively remove aggregated tau proteins associated with Alzheimer's disease in mice. The approach utilises TRIM21 to target tau aggregates, leaving healthy tau intact, and demonstrates potential for other brain disorders driven by protein aggregation.
Researchers used AlphaFold2 to predict structural effects of mutations on protein stability, finding correlations between small structural changes and stability changes. This breakthrough opens up new possibilities for protein engineering, enabling scientists to design proteins with specific functions more effectively.
UMass Amherst researchers have identified the 'quality control' regulator for protein folding, a crucial process that ensures essential cellular functions. The discovery of this regulator, Sep15, could lead to new treatments targeting misfolded proteins associated with diseases like Alzheimer's and cystic fibrosis.
Protein misfolding is a critical factor in neurodegenerative diseases. CRISPR/Cas9 technology allows precise modifications of genes associated with these disorders, potentially halting or reversing disease progression.
Researchers have discovered that ribosomes play a crucial role in protein folding, directing folding pathways by impacting energy and stability. This discovery reveals the structural basis of how ribosomes affect protein folding, offering new insights into diseases such as cancers.
A UAB study found that lower transthyretin levels are associated with an increased risk of heart failure and all-cause mortality. The research highlights the importance of TTR levels in predicting heart disease risk, particularly for individuals carrying the V142I gene variant.
Researchers from Jilin University provide a comprehensive overview of brain injury biomarkers, including neuron-specific enolase, ubiquitin C-terminal hydrolase-L1, and neurofilament proteins. These biomarkers can help identify brain injuries and predict disease progression.
Researchers at the University of Cambridge have developed an atlas of proteins that reveals how they behave inside human cells. The tool allows for the identification of new proteins involved in important bodily functions, including fat distribution and protein creation.
A team of scientists from Max Planck Institute found that extremely long-lived proteins in the ovary play a crucial role in preserving fertility. These proteins, known as chaperones, help maintain cellular processes and prevent misfolded proteins from aggregating.
Researchers develop a method that fuses AlphaFold's strengths with computer simulations based on physics laws to predict protein structures, enabling faster drug development. The approach filters down initial hypotheses to a more manageable set of structures, increasing the effectiveness of pharmaceuticals.
Two studies by Prof. Lucía Chávez Gutiérrez's team reveal the role of gamma-secretase inhibition and amyloid plaque composition in AD. Aβ42 fragments impede gamma-secretase function, while multimodal mass spectrometry imaging reveals diverse plaque compositions.
Researchers at Johns Hopkins Medicine identified a potentially new biological target involving Aplp1, which drives the spread of Parkinson's disease-causing alpha-synuclein. The findings suggest targeting this interaction with drugs could slow Parkinson's disease progression and other neurodegenerative diseases.
A new study reveals how the FUS protein behaves in ALS and FTD, mirroring what is observed in human diseases where protein aggregates spread and contribute to neurodegeneration. The research supports the broader hypothesis that many neurodegenerative diseases involve prion-like mechanisms.
A groundbreaking study reveals zwitterionic polymers can inhibit protein aggregation, a key mechanism behind various human diseases. The researchers found that hydrophobicity and molecular weight impact protein stabilization, offering new avenues for therapeutic strategies.
A new hypothesis paper proposes that Parkinson's disease starts in either the brain's smell center or the body's intestinal tract, tied to environmental factors. The study suggests that exposure to pesticides, air pollution, and tainted food may predispose to the disease.
Scientists discovered that tiny brain bubbles called small extracellular vesicles carry more complete instructions for altering cellular function than previously thought. Researchers found nearly 80% of identified mRNAs were full-length, allowing them to be transcribed by recipient cells into viable proteins.
Researchers found that impaired mitochondrial unfolded protein response causes accelerated telomere shortening in both oocytes and somatic cells of aging mice. This study highlights the link between loss of mitochondrial protein homeostasis, infertility, and somatic aging.
Researchers discovered that aggregates prevent silencing of stress response in brain cells, leading to cell death. A new treatment involves administering a drug to turn off the stress response and keeping SIFI turned on to clean up protein aggregates.
Post-translational modifications on alpha-synuclein slow amyloid aggregation and protect neurons, potentially slowing disease progression. The study's findings suggest that targeting these modifications could lead to new treatments for Parkinson's disease.
Researchers have discovered a key enzyme that stops cancer cell death and found it plays a pro-survival function in cancer cells. This finding provides crucial information for developing new cancer-fighting strategies.
Researchers have discovered a protein called NEMO that prevents the formation of toxic protein aggregates in Parkinson's disease. By labeling proteins for degradation and interacting with autophagy machinery, NEMO promotes the breakdown of harmful aggregates, potentially leading to new therapeutic strategies.
A team of researchers at UMass Amherst has discovered a crucial role played by the enzyme UGGT in protein folding. The study reveals how UGGT 'tags' misfolded proteins with specific sugars, enabling chaperones to identify and correct errors.
Researchers found that misfolded prion proteins can trigger the clumping of TDP-43 in nerve cells, leading to reduced splicing activity and altered protein expression. This study reveals a new mechanism of how disease-associated prion proteins affect physiological signaling pathways through cross-seeding.
Cells employ a protective mechanism to preserve orphan ribosomal proteins during heat shock, allowing for rapid recovery once the stress subsides. This study uses lattice light sheet 4D imaging and pulse labeling with HaloTag dye to visualize these processes in real-time.
Researchers at Chalmers University of Technology have shown that graphene oxide nanoflakes can reduce the accumulation of misfolded amyloid peptides in yeast cells, which are similar to human neurons affected by Alzheimer's disease. This suggests that graphene oxide may hold great potential for treating neurodegenerative diseases.
Researchers have discovered a peptide that stabilizes the normal structure of alpha-synuclein protein, preventing misfolding and toxic clumps. This breakthrough could lead to new therapeutic developments for neurodegenerative diseases like Parkinson's.
Researchers identified potential therapeutic targets for Alzheimer's disease and other conditions using a new approach combining AI-driven target identification with protein phase separation analysis. The study provides insights into the role of protein phase separation in human disease and its potential as a therapeutic target.
Researchers at Aarhus University have unraveled the mystery of how lipid layers on cell surfaces accelerate Parkinson's disease misfolding. The study reveals that elevated concentrations cause alpha-synuclein to adopt an upright conformation, leading to easier refolding into dangerous aggregates.
Researchers discovered a new mechanism underlying the heat shock response in Escherichia coli. IbpA suppresses σ32 translation, regulating Hsp expression and aiding cell protection under high temperatures. This finding sheds light on bacterial adaptation to harsh environments.